considerations for trainers coaching glp-1 therapy Everyone Should be on a Medication” “Should everyone just be on a GLP- 1?” Wrong question. The real question is: How do we USE GLP-1s effectively? Because this isn't GLP-1 vs. lifestyle The lead study author and

Defines two types of polycystic kidney disease and describes their genetic origins, symptoms, diagnosis, and treatment, as well as ongoing research.

Learn why Ozempic causes vomiting, how long it lasts, and proven ways to manage nausea

said on May 2 that it gained exclusive development and commercial rights to Hangzhou, China-based Sciwind Biosciences Co

Missing a semaglutide dose can feel stressful, but taking it two days late is often manageable if you follow the right steps

Ensuring equitable access and strengthening health systems will be essential to prevent widening health disparities.AgendaCo-chairsDr Luz de Regil Director, Department of Nutrition and Food Safety, WHO and Dr Kirsten Bibbins Domingo Editor-in-Chief, JAMAModeratorDr Gaya Manori Gamhewage, Director, Department of Communication, WHOWelcomingDr Luz De Regil Director NFS, WHO and Dr Kirsten Bibbins-Domingo, Editor-in-Chief, JAMAPresentation:WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adultsDr Francesca Celletti, Senior Advisor Obesity, Department of Nutrition and Food Safety, WHO and Dr